Inozyme Pharma Inc (NASDAQ:INZY) shares, rose in value, with the stock price down by -4.40% to the previous day’s close as strong demand from buyers drove the stock to $0.92.
Actively observing the price movement in the last trading, the stock closed the session at $0.96, falling within a range of $0.9051 and $1.0061. The value of beta (5-year monthly) was 1.388. Referring to stock’s 52-week performance, its high was $6.24, and the low was $0.72. On the whole, INZY has fluctuated by -7.94% over the past month.
With the market capitalization of Inozyme Pharma Inc currently standing at about $59.07 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-09.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that INZY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of INZY currently trading nearly -0.66% and -15.39% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.28, while the 7-day volatility ratio is showing 10.87% which for the 30-day chart, stands at 11.98%. Furthermore, Inozyme Pharma Inc (INZY)’s beta value is 1.30, and its average true range (ATR) is 0.11.
A comparison of Inozyme Pharma Inc (INZY) with its peers suggests the former has fared considerably weaker in the market. INZY showed an intraday change of -4.40% in last session, and over the past year, it shrunk by -81.04%%.
Data on historical trading for Inozyme Pharma Inc (NASDAQ:INZY) indicates that the trading volumes over the past 10 days have averaged 0.47 and over the past 3 months, they’ve averaged 610.47K. According to company’s latest data on outstanding shares, there are 64.24 million shares outstanding.
Nearly 32.23% of Inozyme Pharma Inc’s shares belong to company insiders and institutional investors own 59.10% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.21 million shares as on 2025-03-31, resulting in a short ratio of 8.11. According to the data, the short interest in Inozyme Pharma Inc (INZY) stood at 708.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 4.39 million. The stock has fallen by -66.81% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the INZY stock heading into the next quarter.
